Anti-CGRP monoclonal antibodies counteract establishment of food aversive memories and chemotherapy-induced anorexia and weight loss., PMID:40490094
Genetic variants and characterization of MODY in a single, large pediatric referral center., PMID:40486976
The evolution of the therapeutic concept 'GIP receptor antagonism'., PMID:40469445
Real-world evaluation of the efficacy and safety of switching from weekly dulaglutide to weekly semaglutide: The SEMA-SWITCH study., PMID:40450456
Pharmacovigilance analysis of neurological adverse events associated with GLP-1 receptor agonists based on the FDA Adverse Event Reporting System., PMID:40413246
Efficacy, Safety, and Future of GLP-1 Receptor Agonists: A Systematic Literature Review and Meta-Analysis., PMID:40409279
Nutrition support whilst on glucagon-like peptide-1 based therapy. Is it necessary?, PMID:40401903
"Satiety molecules" - nesfatin-1 and glucagon-like peptide 1 in blood serum in patients with anorexia nervosa and obesity., PMID:40331844
From Prescription to Predicament: A Case of Semaglutide-Induced Discoid Lupus Erythematosus in an Adult Male Patient., PMID:40330408
A phase 1, randomized, double-blind, placebo-controlled trial investigating the safety, tolerability, pharmacokinetics, and pharmacodynamics of KN056 (a recombinant human GLP-1 variant Fc fusion protein) in healthy Chinese participants., PMID:40328758
GIPR-Ab/GLP-1 peptide-antibody conjugate requires brain GIPR and GLP-1R for additive weight loss in obese mice., PMID:40301582
Effects of GLP-1 Analogues and Agonists on the Gut Microbiota: A Systematic Review., PMID:40284168
GLP- 1R status using validated monoclonal antibody in 689 cases of neuroendocrine neoplasm and its correlation with somatostatin receptor scintigraphy, insulin production, and histological grades., PMID:40281248
A Case of Pulmonary Hemorrhage, Supratherapeutic International Normalized Ratio (INR), and Anti-neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis: Unmasking a Potential Link to Tirzepatide., PMID:40225446
Where are we now? Biased signalling of Class B G protein-coupled receptor-targeted therapeutics., PMID:40216261
Efficacy and Safety of Dulaglutide Biosimilar LY05008 Versus the Reference Product Dulaglutide (Trulicity) in Chinese Adults With Type 2 Diabetes Mellitus: A Randomized, Open-Label, Active Comparator Study., PMID:40214296
Comparative efficacy and tolerability of currently approved incretin mimetics: A systematic analysis of placebo-controlled clinical trials., PMID:40212008
Unveiling the Therapeutic Potential of Dulaglutide in Mitigating Tacrolimus-Induced Nephrotoxicity Through Targeting the miR-22/HMGB-1/TLR4/MyD88/NF-κB Trajectory., PMID:40205909
Comparison of Dose Escalation Versus Switching to Tirzepatide Among People With Type 2 Diabetes Inadequately Controlled on Lower Doses of Dulaglutide : A Randomized Clinical Trial., PMID:40183678
First-in-Human Study on Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Escalating Doses of HEC88473, a Novel Dual GLP-1 and FGF21 Receptor Agonist in Healthy and Obese Chinese Subjects., PMID:40175670
Research Progress on the Influence of Novel Targeted Drugs for Osteoporosis on Glucose Metabolism., PMID:40149867
Real world initiation of newly funded empagliflozin and dulaglutide under special authority for patients with type 2 diabetes in New Zealand., PMID:40140836
Influence of Combination Therapy with Dulaglutide or Liraglutide and SGLT2 Inhibitors on Renal Outcomes in Patients with Type 2 Diabetes: A Post-hoc Analysis of the RECAP Study., PMID:40105226
Anti-diabetic Biologicals: Exploring the Role of Different Analytical Techniques., PMID:40088445
Multifunctional incretin peptides in therapies for type 2 diabetes, obesity and associated co-morbidities., PMID:40081498
Exploring Connections Between Weight-Loss Medications and Thyroid Cancer: A Look at the FDA Adverse Event Reporting System Database., PMID:40055991
Sex Differences in the Efficacy of Glucagon-Like Peptide-1 Receptor Agonists for Weight Reduction: A Systematic Review and Meta-Analysis., PMID:40040445
Advances in Oral Biomacromolecule Therapies for Metabolic Diseases., PMID:40006605
Glucagon-Like Peptide 1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors Improve Renal Resistive Index in Patients With Type 2 Diabetes: A 26-Week Prospective Observational Real-Life Study., PMID:39963363
Population Pharmacokinetics of Efsubaglutide Alfa in Healthy Subjects and Subjects with Type 2 Diabetes., PMID:39961992
Dulaglutide accelerates diabetic wound healing by suppressing Nrf2-dependent ferroptosis in diabetic mice., PMID:39954860
Newer Glucagon-Like Peptide-1 Receptor Agonists Are Associated With Improved Glycemic Control in US Adults With Type 2 Diabetes: A Population-Level Time Series Analysis., PMID:39947393
Identification of a pathogenic founder variant in the WFS1 gene that causes Wolfram syndrome in the Druze population., PMID:39944315
Cutting-edge biotherapeutics and advanced delivery strategies for the treatment of metabolic dysfunction-associated steatotic liver disease spectrum., PMID:39923856
Improvement in Helicobacter pylori Eradication Among Adults Receiving Semaglutide: A Population-Based Propensity-Score-Adjusted Analysis., PMID:39902748
Epigenetic dysregulation of metabolic programs mediates liposarcoma cell plasticity., PMID:39896505
Association between glucagon-like peptide-1 agonists and risk of diabetic retinopathy: a disproportionality analysis using FDA adverse event reporting system data., PMID:39873334
[Search for new immunohistochemical and circulating markers of insulinoma]., PMID:39868444
Is Weight Loss the Main Driver for A1C Improvement by Glucagon-Like Peptide 1 (GLP-1) Receptor Agonists? A 2.5-Year Analysis in Real-World Clinical Practice., PMID:39853913
Short- and long-term glycemic effects of pasireotide in patients with acromegaly: a comprehensive case study with review of literature., PMID:39842795
Effect of the glucagon-like peptide-1 receptor agonists dulaglutide on kidney outcomes in db/db mice., PMID:39805329
Renoprotective effects of dulaglutide, a GLP-1 agonist, involving regulation of epithelial-mesenchymal transition in patients with type 2 diabetes and diabetic kidney disease., PMID:39790030
Selective Colocalization of GHSR and GLP-1R in a Subset of Hypothalamic Neurons and Their Functional Interaction., PMID:39737802
Reduction of Hepatic Fat Content by Dulaglutide for the Treatment of Diabetes Mellitus: A Two-Centre Open, Single-Arm Trial., PMID:39718468
Differential effects of liraglutide naltrexone/bupropion, and caloric restriction on metabolic parameters and beta-cell regeneration in type 2 diabetic rat model: role of beta arrestin 1., PMID:39704859
The Cardiovascular Outcomes Between Liraglutide and Dulaglutide Among Different Chronic Kidney Disease Stages in Patients With Type 2 Diabetes., PMID:39689782
Use of glucagon-like peptide type 1 receptor agonists in kidney transplant recipients., PMID:39645509
The combination of a glucagon-like peptide-1 and amylin receptor agonists reduces alcohol consumption in both male and female rats., PMID:39639536
Synergistic-like decreases in alcohol intake following combined pharmacotherapy with GLP-1 and amylin in male rats., PMID:39622492
Improved glycemic and weight control with Dulaglutide addition in SGLT2 inhibitor treated obese type 2 diabetic patients at high cardiovascular risk in a real-world setting. The AWARE-2 study., PMID:39613122
For research use only. Not for human or drug use.
